Bodybuilding Health+ Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

01Start with the entity behind the offer

Bodybuilding Health+ describes itself as a patient-management platform working with independent physicians and other practitioners. Its terms identify Dynamo Group LLC as the operator and explicitly state that using the platform does not create a doctor-patient relationship with Dynamo Group. That distinction matters when evaluating the offer: the company arranging access is not necessarily the entity responsible for an individual clinical decision. The consulted documents do not name the treating medical groups, individual practitioners or partner pharmacies.

The platform’s stated scope extends beyond weight management. Its three core programs are medical weight management, longevity and optimization, and sexual-performance support. For the weight-management program, prescription products require an online evaluation by an independent licensed healthcare provider and are prescribed only when clinically suitable. Payment does not guarantee either prescribing or dispensing. These are meaningful qualifications to the shopping-style presentation, but they do not independently verify credentials or establish clinical quality. Our guide to what public provider documents can prove explains that distinction.

02The product description stops short of the clinical evidence

The homepage names compounded semaglutide and compounded tirzepatide and states that neither preparation is FDA approved or evaluated by FDA for safety, effectiveness or quality. The consulted documentation does not establish their administration route, complete formulation, concentration or supplied quantity. It also does not identify the dispensing pharmacy. These omissions prevent a precise product-level comparison with research on approved medicines. They do not justify assuming a particular route, added ingredient, salt form or manufacturing practice.

FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That recommendation is not a blanket conclusion about this platform. Nonapproval alone neither proves clinical inequivalence nor establishes equivalence. A useful next question is what exact preparation the clinician proposes and why it meets the individual’s needs. The distinction between approved medicines and compounded preparations is an evidence question, not simply a choice between two labels.

03Published trials are not Bodybuilding Health+ outcome reports

STEP 1 studied subcutaneous semaglutide in adults with obesity, or overweight plus a weight-related condition, without diabetes, over 68 weeks. SURMOUNT-1 studied subcutaneous tirzepatide in a similar broadly defined population without diabetes over 72 weeks. Neither was a study of Bodybuilding Health+ or its compounded preparations. Both also involved tolerability considerations, including gastrointestinal adverse effects. Novo Nordisk funded STEP 1; Eli Lilly funded SURMOUNT-1. Their findings cannot establish outcomes for this platform, an unspecified formulation or an individual patient.

The homepage displays product review counts and promotional benefit statements, but those are not substitutes for controlled research or a documented provider-outcomes analysis. The consulted pages do not present provider-specific weight-loss results with a defined population, follow-up period and accounting for people who discontinued. That does not establish that care is ineffective; it limits what can be claimed from these documents. Readers should keep clinical trials separate from company performance claims, particularly when a familiar ingredient name appears beside consumer ratings.

04What the advertised bundle prices actually show

Bodybuilding Health+ publishes monthly figures attached to four bundle durations for each compounded GLP-1. The table preserves those figures as advertisements, not verified installment schedules or purchase totals. The pages do not establish the initial amount collected, whether a longer bundle requires prepayment, or whether consultation, follow-up, laboratory work, supplies and shipping are included. A duration label also does not establish medication quantity or a minimum contractual commitment. Those details need a separate written explanation before the displayed monthly figure can describe the purchase adequately.

The tirzepatide 12-month option is labeled “Best Value,” although its advertised $187.33 monthly amount exceeds both the three-month and six-month figures. The consulted pages do not explain that discrepancy. The advertised savings are the provider’s claims, not independently verified savings calculations. More broadly, nothing in this price display establishes a price lock, later renewal rate or automatic-renewal schedule. The terms authorize the amount due to be charged after payment information and a request are submitted, but do not resolve those bundle-specific questions.

05Trace the handoffs from intake to delivery

The advertised process begins with an online medical questionnaire covering goals and medical history. The homepage says a U.S.-licensed healthcare professional reviews that intake and builds a personalized plan; that is the provider’s description, not an independent credential check. The service is presented as fully online, with no required in-person visits. Access also requires registration and an account. The public pages do not establish how quickly review occurs, whether a live visit is used, or which clinical records or laboratory tests might be required.

If a prescription is approved, the homepage says a partner pharmacy fills it unless the patient specifies another licensed pharmacy. Dynamo Group states that it does not manufacture, dispense or control medication formulations. Medication is advertised as shipped to the home, but the terms do not guarantee delivery timelines and disclaim responsibility for specified third-party pharmacy and shipping problems. Preparation, dispatch and arrival dates remain undocumented. For injectable GLP-1 products that arrive warm or insufficiently refrigerated, FDA explicitly advises not using the product and contacting the provider or dispensing pharmacy.

06Follow-up and access need more than a broad promise

The homepage promises ongoing provider check-ins as goals evolve, without specifying their frequency, format or response time. It does not establish how patients reach the prescriber between check-ins, who handles adverse-effect questions or whether additional encounters cost extra. NIDDK describes follow-up as attention to response and tolerability, not merely continued payment. A practical evaluation therefore asks who reviews progress, how concerns are escalated and what happens if treatment is not suitable. Our discussion of clinical follow-up versus renewal notices develops those questions.

General platform eligibility requires being at least 18 and living in the United States in a location where services are available. The terms say only certain states are served and direct readers to support for the current list, so nationwide access is not established. Meeting those basic requirements does not guarantee service; practitioners may apply additional case-specific criteria. Although the privacy policy lists BMI and other health information among collected data, that does not establish a prescribing threshold. The consulted pages also do not confirm Spanish-language care or interpretation.

07Payment responsibility and stopping treatment are separate issues

The terms say affiliated medical professional entities are not contracted providers with commercial, government or other health insurance plans, and assign patients responsibility for all fees due. That is not evidence of a government-insurance enrollment exclusion, nor does it settle an individual plan’s medication coverage. Payment authorization names Dynamo Group, CareValidate, affiliates and third-party processors; the consulted documents do not clearly explain CareValidate’s role. Before paying, readers can request the billing entity, initial charge and an itemized explanation of which services the quoted amount purchases.

Refund boundaries are clearer than cancellation mechanics. Consultation fees are nonrefundable once a consultation is received; prescription returns for reuse or resale are not accepted, and the terms call all sales final. A separate clause allows users to terminate the terms by discontinuing platform use, but does not explain how to cancel a bundle or prevent future charges. Renewal timing, cancellation notice, unused balances and later pricing remain unresolved. The terms also provide binding arbitration, a qualifying small-claims exception, no class or representative actions, and a 30-day arbitration opt-out process.

08The broader catalog and data practices complete the picture

The non-GLP-1 catalog reinforces that this is a broader treatment-access business. NAD+ starts at $129/month; sermorelin starts at $129/month and is advertised in injection or tablet form. Topical GHK-Cu starts at $129/month, glutathione injection at $179/month and PT-141 injection at $169/month. These listings do not establish included quantities. The “Tadalafil & Sildenafil” block starts at $96/month and lists six units for one month, 12 for two and 18 for three, without assigning separate option prices. Daily tadalafil starts at $115/month with a one-month supply.

The privacy policy lists height, weight, BMI, medications, pregnancy, breastfeeding and certain surgical procedures among health data collected. It says personal information will not be sold, rented or leased, while the homepage permits operational and marketing uses, including hashed or de-identified data for Google or Meta audience targeting and exclusion. That is not a promise of no advertising-related data use. SMS participation is voluntary and not required for purchase. Published contact channels are support@bbhealthplus.com and +1 866 236-8417; the operator lists 1 Town Center Road, Suite #675, Boca Raton, Florida 33486.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
5. Bodybuilding Health+ — terms of service ↗
6. Bodybuilding Health+ — official website ↗
7. Bodybuilding Health+ — privacy policy ↗

Continue reading

• What Public GLP-1 Provider Documents Can—and Cannot—Prove
• FDA-Approved Medicines and Compounded Preparations: Separate Evidence Questions
• A Clinical Trial Is Not a Telehealth Company Performance Report
• Follow-up Is a Clinical Question, Not Just a Renewal Notice